Cancer and Leukemia Group B
55 Years of Excellence in Cancer Research
Welcome to Boston!

2011 Cancer and Leukemia Group B Summer Group Meeting

The first randomized clinical trial in oncology, led in 1956 by Emil (Tom) Frei, James F. Holland, and George Sellkirk, was conducted by a multi-institutional consortium known as the Acute Leukemia Cooperative Group, which eventually gave rise to the Cancer and Leukemia Group B. In the 55 years since its beginning, the CALGB has conducted more than 850 clinical trials in a wide range of cancers, spanning all disciplines of oncology research and practice. The impact for patients and their families has been tremendous. The CALGB has never rested upon past success, but has continually adapted to push the field forward. As a result, the structure and scope of the Group has grown dramatically over the years. We are now entering a new phase in this process, and this will be the final Group meeting for the CALGB in its current configuration. Beginning this fall, the CALGB will join together with researchers in the North Central Cancer Treatment Group and the American College of Surgeons Oncology Group to form a new, expanded cancer cooperative group.

Although more patients than ever before are successfully treated, cancer still has a great impact upon our world. Bold advances are needed to ensure that new discoveries can be advanced as rapidly as possible. The current era of genomic medicine and targeted therapeutics dramatically increased the demands upon our clinical trials system. This new cooperative group will combine the talents and resources of three outstanding organizations, ensuring that our research team has the best possible tools to conduct high-impact clinical and translational research.

I welcome you all to this final CALGB Group meeting, which will be a time of reminiscing about the past and looking forward to an exciting future.

Enjoy the meeting, and be sure to join for the inaugural meeting of the new Group in November.

Monica M. Bertagnolli, M.D.
Group Chair
### Schedule At-a-Glance

All sessions are being held at the Sheraton Boston Hotel.

#### THURSDAY / June 23

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 am - 1 pm</td>
<td>SoCRA Certification Exam</td>
</tr>
<tr>
<td>1 pm - 5 pm</td>
<td>CRA Committee</td>
</tr>
<tr>
<td>4 pm - 7 pm</td>
<td>GCO/SC/CO Directors Meeting Closed Session</td>
</tr>
<tr>
<td>5:10 pm - 7:10 pm</td>
<td>Prevention Committee</td>
</tr>
<tr>
<td>5:30 pm - 8 pm</td>
<td>Audit Preparation Workshop</td>
</tr>
<tr>
<td>6 pm - 9 pm</td>
<td>CARE Patient Advocate Subcommittee</td>
</tr>
<tr>
<td>7:10 pm - 9 pm</td>
<td>CCHO Steering Committee Closed Session</td>
</tr>
</tbody>
</table>

#### FRIDAY / June 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 am - 7 pm</td>
<td>Registration</td>
</tr>
<tr>
<td>7:30 am - 12 pm</td>
<td>CALGB Executive Committee Closed Session</td>
</tr>
<tr>
<td>8 am - 12 pm</td>
<td>CRA Continuing Education Session</td>
</tr>
<tr>
<td>10 am - 11 am</td>
<td>Constitution Committee Closed Session</td>
</tr>
<tr>
<td>10 am - 12 pm</td>
<td>CCHO Symptom Intervention Subcommittee</td>
</tr>
<tr>
<td>10 am - 12:10 pm</td>
<td>Imaging Committee</td>
</tr>
<tr>
<td>10 am - 1 pm</td>
<td>Leukemia/Leukemia Correlative Sciences Committees</td>
</tr>
<tr>
<td>10 am - 1 pm</td>
<td>Respiratory Committee</td>
</tr>
<tr>
<td>11 am - 12:30 pm</td>
<td>Audit Committee Closed Session</td>
</tr>
<tr>
<td>11 am - 4 pm</td>
<td>Data and Safety Monitoring Board Closed Session</td>
</tr>
<tr>
<td>12:30 pm - 2 pm</td>
<td>IPEC Committee Closed Session</td>
</tr>
<tr>
<td>12:30 pm - 2:10 pm</td>
<td>Oncology Nursing Educational Session</td>
</tr>
<tr>
<td>12:30 pm - 2:10 pm</td>
<td>COMMONWEALTH / 3RD FLOOR</td>
</tr>
<tr>
<td>1 pm - 3 pm</td>
<td>CCHO Health Outcomes Subcommittee/Jimmie Holland Lecture</td>
</tr>
<tr>
<td>2 pm - 3 pm</td>
<td>Membership Committee Closed Session</td>
</tr>
<tr>
<td>2 pm - 4 pm</td>
<td>Correlative Science Symposium</td>
</tr>
<tr>
<td>2 pm - 5 pm</td>
<td>Transplant Committee</td>
</tr>
<tr>
<td>3 pm - 5 pm</td>
<td>CALGB Board of Directors Closed Session</td>
</tr>
<tr>
<td>3 pm - 5 pm</td>
<td>CRA Workshop for Cancer Control Studies</td>
</tr>
<tr>
<td>4 pm - 5:30 pm</td>
<td>Biospecimen and Correlative Science Advisory Closed Session</td>
</tr>
<tr>
<td>5:30 pm - 6:30 pm</td>
<td>CALGB Foundation Board of Trustees Closed Session</td>
</tr>
<tr>
<td>7 pm - 10 pm</td>
<td>DINNER RECEPTION</td>
</tr>
</tbody>
</table>

#### SATURDAY / June 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 am - 4 pm</td>
<td>Registration Closed During Plenary Session</td>
</tr>
<tr>
<td>8 am - 9 am</td>
<td>Conflict of Interest Committee Closed Session</td>
</tr>
<tr>
<td>8 am - 10 am</td>
<td>CCOP Committee</td>
</tr>
<tr>
<td>8 am - 10 am</td>
<td>Pathology Committee</td>
</tr>
<tr>
<td>8 am - 10 am</td>
<td>Surgery Committee</td>
</tr>
<tr>
<td>8 am - 10 am</td>
<td>Cancer in the Elderly Committee</td>
</tr>
<tr>
<td>8 am - 10 am</td>
<td>PET Committee</td>
</tr>
<tr>
<td>8 am - 10 am</td>
<td>Statistical Symposium</td>
</tr>
<tr>
<td>10 am - 1 pm</td>
<td>PLENARY SESSION</td>
</tr>
<tr>
<td>1 pm - 2:30 pm</td>
<td>Young Investigators Luncheon By Invitation Only</td>
</tr>
<tr>
<td>1 pm - 3 pm</td>
<td>CARE Review</td>
</tr>
<tr>
<td>11:30 pm - 1:30 pm</td>
<td>CER Working Group</td>
</tr>
<tr>
<td>2 pm - 4 pm</td>
<td>Radiation Oncology Committee</td>
</tr>
<tr>
<td>2 pm - 5 pm</td>
<td>Breast Committee</td>
</tr>
<tr>
<td>2 pm - 5 pm</td>
<td>GU Committee</td>
</tr>
<tr>
<td>2 pm - 5 pm</td>
<td>GI Committee</td>
</tr>
</tbody>
</table>
**DISEASE COMMITTEES**

**Breast Committee**

**Session Agendas**

Saturday, June 25, 2 pm - 5 pm; Constitution Ballroom, 2nd Floor

Co-Chairs
- Clifford Hudis, M.D.
- Eric Winer, M.D.

Vice Chairs
- Matthew Ellis, M.D., B.Chr., Ph.D.
- Lyndsay Harris, M.D.
- Charles Perou, Ph.D.

**Introduction / Review of Group Merger Plan**

Clifford Hudis, M.D.

**Protocol Review**

Active:

- **CTSU S0800** A randomized phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) (NSC-736361) with or without bevacizumab, either preceded by or followed by Q2 week doxorubicin (A) and cyclophosphamide (C) plus pegylated liposomal doxorubicin (peg-FPG) as neoadjuvant therapy for inflammatory and locally advanced HER-2/neu negative breast cancer

- **40061** Randomized phase II trial of paclitaxel combined with trastuzumab, lapatinib, or both as neoadjuvant therapy for HER2-positive primary breast cancer

- **40063** Randomized phase II 2x2 factorial trial of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC in hormone receptor-negative/HER2-negative regionally recurrent breast cancer

- **40503** Endocrine therapy with or without anti-VEGF therapy: A randomized phase III trial of endocrine therapy alone or endocrine therapy plus bevacizumab (NSC-704985: IND 7921) for women with hormone receptor-positive advanced breast cancer

- **40502** A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin-bound Nab-paclitaxel or oxaplatin combined with bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer

Closed:

- **150007** Contrast-enhanced breast MRI and correlative studies to characterize tumor response in patients undergoing neoadjuvant treatment for locally advanced breast cancer

- **150012** Contrast-enhanced breast MRI for evaluation of patients undergoing neoadjuvant treatment for locally-advanced breast cancer

- **CTSU E5103** A double-blind phase III trial of doxorubicin and cyclophosphamide followed by paclitaxel with bevacizumab or placebo with lymph node-positive and high-risk lymph node-negative breast cancer

In Development:

- **40903** Phase II study of neoadjuvant letrozole for post-menopausal women with estrogen receptor positive ductal carcinoma in situ (DCIS)

- **41101** A randomized phase III trial of eribulin compared to physicians choice of paclitaxel, nanoparticle albumin-bound (nab-paclitaxel), or capecitabine as first or second-line therapy for locally recurrent or metastatic breast cancer

- **E. Shelly Hwang, M.D.**

- **Nadine Jasson, M.D.**

**Correlative Science Update**

Matthew Ellis, M.D., B.Chr., Ph.D.

Charles Perou, Ph.D.

**Reports from Liaisons**

- **Weight Loss and Exercise Intervention**
  - Jennifer Lichtblau, M.D.

- **NCCTG Trials**
  - Edith Perez, M.D., Mayo Clinic, NCCTG

- **ACOSOG Trials**
  - Kelly Hunt, M.D., MD Anderson, ACOSOG

**GI Committee**

**Session Agendas**

Saturday, June 25, 2 pm - 5 pm; Back Bay C, 2nd Floor

Co-Chairs
- Clifford Hudis, M.D.
- Eric Winer, M.D.

**Allied Approach to Pancreas Cancer**

Steven Alberts, M.D., Co-Chair, NCCTG GI Committee

**Hedy Kindler, M.D., University of Chicago**

**Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80030**

- Andrew Nixon, Ph.D., Director, Duke Molecular Reference Laboratory

**Protocol Review**

**Active**

- **80405** A phase III trial of inotucumab (5-FU/leucovorin) or oxaliplatin (5-FU/leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum

- **80701** Randomized phase II study of bevacizumab alone, in combination with everolimus, or in combination with temozolomide in patients with locally advanced or metastatic pancreatic neuroendocrine tumors

- **Matthew kalé, M.D., M.M.Sc.**

**80702** A phase III trial of 6 v. 12 treatments of adjuvant FOLFOX with or without cetuximab therapy for patients with stage III colon cancer

**Jeffrey Meyerhardt, M.D., M.P.H.**

**GI Correlative Science Report**

- **Ngoc Minh, M.D.**

**GI Surgery Subcommittee Report**

- **Perry Shen, M.D.**

**In Development**

- **81001/N1048/Z6092** Neoadjuvant FOLFOX without planned pelvic radiation therapy for good risk locally advanced rectal adenocarcinoma

- **Deborah Schrag, M.D.**

- **81002/N0949** Randomized phase II trial of nifOLFOX plus bevacizumab versus 5-fluorouracil or capecitabine plus bevacizumab as first-line treatment in elderly patients (+70 years old) with metastatic colorectal cancer

- **Nadine Jasson, M.D.**

- **81003** Phase IB/II randomized phase II study of FOLFIRINOX plus AMG-479 or placebo in patients with previously untreated, metastatic pancreatic adenocarcinoma

- **Brian Weir, M.D.**

**Propective randomized phase II trial of pazopanib plus depot octreotide versus placebo plus depot octreotide in patients with progressive carcinoid tumors**

- **Emily Berglund, M.D.**

- **81101** Phase 2 study of XL184 in patients with refractory metastatic colorectal cancer stratified by genotype

- **David Ryan, M.D., Eunice Kwak, M.D., and Katie Kelley, M.D.**

A randomized phase II study of FOLFIRINOX plus IP-926, a Hh pathway inhibitor, or FOLRIRINOX plus placebo, followed by radiation with concurrent capetabide, for patients with locallyadvanced pancreatic cancer

- **Andrew Ko, M.D.**

**GI Correlative Science Report**

- **Ngoc Minh, M.D.**

- **GI Surgery Subcommittee Report**

- **Perry Shen, M.D.**

**80802** Phase III randomized study of sorafenib plus docorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

- **Ghassan Abou-Alfa, M.D.**

- **80302** A phase II trial of preoperative inotucenac, cisplatin and radiation in esophageal cancer

- **David van, M.D., Ph.D.**

- **CTSU E1208** A phase III randomized trial of chemoradiotherapy with or without sorafenib in unresectable hepatocellular carcinoma (HCC) in patients with and without vascular invasion

- **Bert O’Neil, M.D.**

- **CTSU NSABP C11** Phase III randomized study of postoperative versus perioperative chemotherapy and bevacizumab in patients with potentially resectable hepatic colorectal metastases

- **CTSU Z6051** A phase III prospective randomized trial comparing laparoscopic assisted resection versus open resection for rectal cancer

- **Martin Weiser, M.D.**

---

**Session Agendas**

**Welcome, Awards and Acknowledgements**

- Monica M. Bertagnolli, M.D.

**CALGB Group Chair**

- Monica M. Bertagnolli, M.D.

**Richard L. Schilsky CALGB Achievement Award Recipient**

- Eric Small, M.D.

- Stanford W. Ascherman and Norman R. Ascherman

**Endowed Chair, and Clinical Professor, Departments of Medicine and Urology**

- University of California at San Francisco

**Reflections: Former Cancer and Leukemia Group B Chairs**

- James Holland, M.D.

**Saturday/June 25, 10 am - 1 pm, Grand Ballroom, 2nd Floor**

- **plenary session**

---

**Cancer and Leukemia Group B Summer Group Meeting 2011**
**GU Committee**

Saturday June 25, 2:15 - 3:30 pm, Commonwealth, 3rd Floor

Chair: Erin Small, M.D.

Vice Chairs: Philip Feibig, M.D., James Monier, M.D.

Protocol Review

**Correlative Science**

Philip Feibig, M.D.

150201 Laboratory studies in hormone refractory prostate cancer: A companion study to CALGB 9480 and 9583

150603 Laboratory studies in metastatic renal cell carcinoma: A companion study to CALGB 9020s

151004 Androgens receptor (AR) activity in castration-resistant prostate cancer (CRPC) and response to ketoconazole

190203 A randomized phase III study of neo-adjuvant docetaxel and androgen deprivation prior to radical prostatectomy versus immediate radical prostatectomy in patients with high-risk, clinically localized prostate cancer

191004 Randomized phase III study of gemcitabine and capcitabine in patients with advanced transitional cell carcinoma of the urinary tract

190802 Randomized phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal cell carcinoma progressing after treatment with sunitinib kinase inhibitors

191002 A randomized, double-blind, placebo-controlled phase III study of依托泊非索单方药物治疗及联合治疗与安慰剂治疗相比对晚期非小细胞肺癌的疗效和安全性

Advanced Prostate Cancer

Michael Morris, M.D.

90202 A randomized, double-blind, placebo-controlled phase II study of early versus standard zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone

**CTSU 50421** Phase II study of docetaxel and atezolizumab versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer

**Leukemia/Leukemia Correlative Sciences Committees**

Saturday June 24, 10 am – 1 pm, Back Bay C, 2nd Floor

Leukemia Chair: Richard A. Larson, M.D.

Vice Chair: Richard M. Stone, M.D.

Corollary Chair: Guido Marrocchi, M.D.

Vice Chair: John C. Byrd, M.D.

Protocol Review

10603 A phase II randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy plus dasatinib (NSC #732517, IND # 73969) and continuation therapy with asaitinib in newly diagnosed patients with core binding factor acute myeloid leukemia (AML)

10001 Phase II study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy plus dasatinib (NSC #732517, IND # 73969) and continuation treatment with asaitinib in newly diagnosed patients with core binding factor acute myeloid leukemia (AML)

Guido Marrocchi, M.D.

11001 A phase II study incorporating soraparin (IND #69996, NSC 7A4772) into the therapy of patients age ≥ 60 years with FLT3 mutated acute myeloid leukemia (AML)

Geoffry Up, M.D.

11002 A randomized phase II trial of dual-targeted therapy with asaitinib and monoclonal antibody to CD47 (IND #201261) in newly diagnosed patients with previously untreated acute myeloid leukemia (AML)

Gail Robaz, M.D.

361006 Geriatric assessment in CALGB 110701

Hedi Klein, M.D.

CTSU 5000 A randomized study of standard cytarabine plus daunomycin (7+3 therapy) versus daunomycin with high-dose cytaraebine (HAC) with or without vorinostat in younger patients with previously untreated acute myeloid leukemia (AML)

Richard Stone, M.D.

CTSU 5000 A randomized phase II study of azacitidine alone versus a combination of azacitidine with vorinostat for higher-risk myelodysplastic syndromes (MDS)

Richard Stone, M.D.

9710 Phase III randomized study of concurrent tretinoin & chemotherapy with or without arsenic trioxide (As2O3) as initial consolidation therapy followed by maintenance therapy with intermittent tretinoin versus intermittent tretinoin plus mercaptopurine and methotrexate for patients with untreated acute promyelocytic leukemia (APL)

Bayard Powell, M.D.

CTSU 50535 A phase II study of ATRA, arsenic trioxide and gemtuzumab ozogamicin in patients with previously untreated high-risk acute promyelocytic leukemia (APL)

Bayard Powell, M.D.

10403 An intergroup, phase II clinical trial for adolescents and young adults with untreated acute lymphoblastic leukemia (ALL)

Wendy Stack, M.D.

10701 A phase II trial of dasatinib (Sprycel) (NSC #77969, NSC #732517) as primary therapy followed by transplantation for adults ≥ 50 years with newly diagnosed Ph+ acute lymphoblastic leukemia by CALGB, ECOG and SWOG

Meir Wetzler, M.D.

CTSU 50805 Phase II study of combination of hyper-CVAD and dasatinib with or without allogenic stem cell transplant in patients with Philadelphia (Ph) chromosome positive and/or BCR-ABL positive acute lymphoblastic leukemia (ALL)

Meir Wetzler, M.D.

10404 A genetic risk-stratified, randomized phase II study of four fluorouracil/leucovorin combinations for patients with symptomatic, previously untreated chronic lymphocytic leukemia

John Byrd, M.D.

11003 A randomized phase II study of CALI011 consolidation in CLL/SLL, assessing time-limited therapy vs. therapy until disease progression

Jennifer Brown, M.D., Ph.D.

In Development

11101 A study of the intravascular and interindividual variability in nilotinib pharmacokinetics and pharmacodynamics in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML)

Mario Boer, M.D.

**Lymphoma Committee**

Friday June 24, 12:30 pm – 3:30 pm, Commonwealth, 3rd Floor

Chair: Bruce Cheson, M.D.

Vice Chairs: Nancy Bartlett, M.D., John Leonard, M.D.

Andrew Zeleznik, M.D., Ph.D.

Peter Martin, M.D.

CTSU 50000 Randomized phase II study comparing bendamustine plus rituximab vs. R-hyperCVAD both followed by transplant for patients with mantle cell lymphoma

Thomas Sheu, M.D.

T-Cell: Relapsed

S1101 Randomized trial of myeloablative versus non-myeloablative consolidation chemotherapy for newly diagnosed primary CNS B-cell lymphoma

Trey Atchelis, M.D.

Hodgkin Lymphoma

S0906 A phase I/II randomized phase II study comparing brentuximab vedotin (SGN-35) to brentuximab vedotin plus lenalidomide for patients with relapsed refractory classical Hodgkin lymphoma

Todd Fehlinger, M.D.

Closed

Hodgkin Lymphoma

S0203 Phase II trial of doxorubicin, vinblastine and gemcitabine (AVG) chemotherapy for non-bulky stage I and II Hodgkin lymphoma

David Strous, M.D.

Primary CNS

S0202 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma

James Rubenstein, M.D., Ph.D.

Follicular: Lymphoma

S0201 A phase II trial of extended induction galiximab (anti-CD20 monoclonal antibody) (BB-IND # 21373) plus rituximab in previously untreated follicular non-Hodgkin lymphoma

Morton Clzonman, M.D.

S0701 A phase II trial of extended induction etoposibum (anti-CD22 monoclonal antibody)(CALGB/INDI 102141) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Barbara Grant, M.D.

Follicular: Relapsed

S0401 A phase II trial of extended induction galiximab (anti-CD20 monoclonal antibody) (BB-IND # 21373) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Morton Clzonman, M.D.

S0701 A phase II trial of extended induction etoposibum (anti-CD22 monoclonal antibody)(CALGB/INDI 102141) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Barbara Grant, M.D.

Follicular: Relapsed

S0401 A phase II trial of extended induction galiximab (anti-CD20 monoclonal antibody) (BB-IND # 21373) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Morton Clzonman, M.D.

S0701 A phase II trial of extended induction etoposibum (anti-CD22 monoclonal antibody)(CALGB/INDI 102141) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Barbara Grant, M.D.

Follicular: Relapsed

S0401 A phase II trial of extended induction galiximab (anti-CD20 monoclonal antibody) (BB-IND # 21373) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Morton Clzonman, M.D.

S0701 A phase II trial of extended induction etoposibum (anti-CD22 monoclonal antibody)(CALGB/INDI 102141) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Barbara Grant, M.D.

Follicular: Relapsed

S0401 A phase II trial of extended induction galiximab (anti-CD20 monoclonal antibody) (BB-IND # 21373) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Morton Clzonman, M.D.

S0701 A phase II trial of extended induction etoposibum (anti-CD22 monoclonal antibody)(CALGB/INDI 102141) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)

Barbara Grant, M.D.

Mantle Cell: Frontline

CTSU E14111 Intergroup randomized phase II four-arm study in patients ≥ 60 with previously untreated mantle cell lymphoma of therapy with: Arm A = rituximab + bendamustine followed by rituximab consolidation (RB --> RB); Arm B = rituximab + bendamustine + bortezomib (RBV --> RB); or Arm C = rituximab + bendamustine followed by lenalidomide + rituximab consolidation (RB --> LR) or Arm D = rituximab + bendamustine + bortezomib followed by lenalidomide + rituximab consolidation (RBV --> LR)

John Leonard, M.D.

Peter Martin, M.D.

CTSU 50000 Randomized phase II study comparing bendamustine plus rituximab vs. R-hyperCVAD both followed by transplant for patients with mantle cell lymphoma

Thomas Sheu, M.D.

New Business / Concluding Comments

Bruce Cheson, M.D.

Bob Dickler, M.D., Ph.D.
STATISTICAL SYMPOSIUM
Cancer Trials of the Future? Biomarker-based Adaptive Design
Saturday, June 25 / 8 am - 10 am
Constitution A / 2nd Floor

Daniel J. Sargent, Ph.D.
CALGB Group Statistician
Professor, Department of Biostatistics and Informatics
Mayo Clinic College of Medicine

Susan Halabi, Ph.D.
CALGB Faculty Statistician
Associate Professor, Biostatistics and Bioinformatics
Department of Biostatistics and Informatics
Duke University

William T. Barry, Ph.D.
CALGB Faculty Statistician
Assistant Professor, Biostatistics and Bioinformatics
Department of Biostatistics and Informatics
Duke University

Donald A. Berry, Ph.D.
CALGB Faculty Statistician
Professor, Department of Biostatistics, Division of Quantitative Sciences
The University of Texas MD Anderson Cancer Center

Come learn about adaptive design in clinical trials. This symposium will focus on the design and implementation of molecular marker-based strategies, using case studies to evaluate benefits and potential risks.

Respiratory Committee
Fridays June 24, 10 am – 1 pm, Constitution Ballroom, 2nd Floor
Chair Jeffrey Volkes, M.D.
Vice Chairs Robert Kraftzke, M.D.

Protocol Overview, Accrual and Manuscripts
Everett Volkes, M.D.
Chair, CALGB Thoracic Committee

Overview of ACOSOG Portfolio
Bryan Meyers, M.D.
Overview of NCCIT Portfolio
Alex Aajo, M.D., Ph.D.

Early Stage Non-Small Cell Lung Cancer
140503 A phase III randomized trial of lobectomy versus limited resection for small (≤2 cm) peripheral non-small cell lung cancer
Noaser Ateka, M.D.

30506 A randomized phase II trial of adjuvant therapy in early stage non-small cell lung cancer associated with banking of frozen specimens and collection of gene expression profile data

David Harpole, M.D., and Robert Kraftzke, M.D.

CTSU E1505 A phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected stage IB/IIA non-small cell lung cancer (NSCCLC)
Stephen Graziano, M.D.

31105 Hypofractionated XRT with adjuvant chemotherapy XRT study
Apar Ganti, M.D., Joseph Salama, M.D., and Jeffrey Bagot, M.D.

New Proposal: Molecular markers and oxygen consumption
David Harpole, M.D., and Robert Kraftzke, M.D.

First Line Stage IV Non-Small Cell Lung Cancer
30607 Randomized, phase II, double-blind placebo-controlled trial of sunitinib (NSC #736511, IND #74019) as maintenance therapy in non-progressing patients following an initial four cycles of platinum-based combination chemotherapy in advanced stage IIIB/IV non-small cell lung cancer
Mark Socinski, M.D., and Maria Boggestrom, M.D.

30801 A randomized phase II study evaluating selective COX-2 inhibition in COX-2 overexpressing advanced non-small cell lung cancer
Martin Edelman, M.D., Michael Mistlond, M.D., Ph.D., and Robert Kraftzke, M.D.

CTSU S0819 A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCCLC)
Michael Penry, M.D.

31103 A phase I randomized trial of duration of chemotherapy in patients with advanced non-small cell lung cancer and performance status of 2
Ajeet Garg, M.D., Rogerio Lilenbaum, M.D., and Jeffrey Crawford, M.D.
SMART chemoradiotherapy
Joseph Salama, M.D.

Second Line Non-Small Cell Lung Cancer
30704 A randomized phase II study to assess the efficacy of pemetrexed or sunitinib (NSC #736511, IND #74019) or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer
Mark Socinski, M.D., and Rebecca Suk-Heist, M.D.

Special Lecture: ASCO 2011 Lung Cancer Update
Rogers Lilenbaum, M.D.

Stage III Non-Small Cell Lung Cancer
30605 Chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III NSCLC patients
Rogers Lilenbaum, M.D.

31101 Individualized combined-modality therapy for patients with locally advanced NSCLC
Ramaswamy Govindan, M.D., and Owen Hahn, M.D.

31102 Hypofractionated XRT for stage III NSCLC
James Urbanic, M.D.

Small Cell Lung Cancer
30504 Combination chemotherapy with or without maintenance sunitinib malate (IND 74019; NSC 736511) for unresected extensive stage small-cell lung cancer A phase II randomized phase I study
Neal Ready, M.D., Ph.D.

30610 Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide
Jeffrey Bagot, M.D., Gregory Masters, M.D., and Rogers Lilenbaum, M.D.

N0922 Phase II randomized study of seneca valley virus-001 (NTX-010) after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
Gregory Otterson, M.D.

Working Group Update
Jeffrey Crawford, M.D., Ravi Salgia, M.D., and Neal Ready, M.D.

Mesothelioma Working Group
Robert Krautzke, M.D., and Fred Kindler, M.D.

Hypofractionated ChemoARTX
James Urbanic, M.D.

30901 Randomized phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy
Arkadiusz Dutek, M.D.

31004 Randomized phase II study of insulin-like growth receptor inhibition in combination with chemotherapy in previously-treated malignant mesothelioma
Priyo Kumar, M.D.

Report from Correlative Science Subcommittee
Robert Krautzke, M.D., and Stephen Graziano, M.D.
Update on antiangiogenic correlative science
Michael Mistlond, M.D., Ph.D.
Cancer and Leukemia Group B
55 Years of Excellence
1956 - 2011
MODALITY COMMITTEES
CANCER IN THE ELDERLY COMMITTEE
Saturday June 25, 8 am - 10 am, Back Bay B, 2nd Floor
Co-Chairs
Harvey Jay Cohen, M.D.
Hyman Muss, M.D.
Protocol Review
Active
361002 Changes in cognitive function in older women treated with standard chemotherapy and cetavizine within CALGB 49907
Rachel Freedman, M.D., M.P.H., and William Bany, Ph. D.
70802 Population-based assessment of cancer trial generalizability in the elderly
Elizabeth Lantam, M.D., MS
Closed / Active Follow-up and New Analyses
49907 A randomized trial of adjunct chemotherapy with standard regimens, cyclophosphamide, methotrexate and fluorouracil - (CMF) or doxorubicin and cyclophosphamide (AC), versus cetavizine in women 65 years and older with positive or node negative breast cancer
Hyman Muss, M.D., Arni Hurns, M.D., and Stuart Lichtman, M.D
369901 Observational cohort study: Chemotherapy decisions and outcomes in women age 65 or older with operable, newly diagnosed breast cancer
Jeanne Mendelblatt, M.D., M.P.H.
361004 Associations between comorbidity, chemotherapy toxicity and clinical outcomes among older women receiving adjuvant therapy for breast cancer in CALGB 49907
Heidi Klepin, M.D.
150106 Tumor markers to predict response in the elderly breast cancer patient (comparison to 49907)
Lynn Dressler, Ph.D., and William Bany, Ph. D.
360401 Development of a geriatric assessment measure for older patients with cancer
Arti Hurns, M.D., Mauna Decker, M.D., and Matthew Mowvaly, M.D.
9793 A phase II trial of CHO-P versus CHO-P and chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in older patients with diffuse mixed, diffuse large cell and immuno- blasto large cell histology non-Hodgkin lymphoma
Vicki Moman, M.D.
For Reference Only
119801 Telephone monitoring: Early identification of physiological distress in cancer patients 65 or more years old during active treatment
Alice Kambli, Ph.D., and Harvey Jay Cohen, M.D.
360001 The effect of an intensive educational program for health care providers on accrual of older persons to cancer treatment protocols
Gretchen Kinman, M.D., MS
60001 Prospective evaluation of the pharmacokinetics, pharmacogenetics and pharmacodynamics of CPT-II and the fluorouracil
Stuart Lichtman, M.D.
9670 Barriers to participation of older women with breast cancer in clinical trials: pilot study
Margaret Kemery, M.D., Hyman Muss, M.D., and Alice Kambli, Ph.D.
70803 Comorbidities and physical functions in older breast cancer survivors
Harvey Jay Cohen, M.D., and Alice Kambli, Ph.D.
360701 Understanding age-related differences in the treatment tolerance and efficacy of paclitaxel for metastatic breast cancer: A pooled analysis of CALGB 9432 adn 9840
Stuart Lichtman, M.D.
70103 Quality of life comparison to 49907
Alice Kambli, Ph.D.
60104 Adherence to oral chemotherapy (comparison to 49907)
Alice Kambli, Ph.D.
In Development
140801 A study to compare surgical choice and recovery as predicted by a brief geriatric assessment for patients 70 years of age and older undergoing surgical resection for lung nodules
Michael Jaklitsch, M.D., and Arni Hurns, M.D.
81002/209491 Randomized phase III trial of mFOLFOX7 plus bevacizumab versus 5-fluorouracil plus bevacizumab as first-line treatment in elderly patients (>70 years old) with metastatic colorectal cancer
Alex Greathy, M.D., and Daniel Sargent, M.D.
70805 A geriatric-specific phone-based psychotherapy for elderly cancer patients with depressive symptoms
Alice Kambli, Ph.D., and Cristin Nelson, Ph.D.
361006 Geriatric assessment in CALGB 11001
Richard Stone, M.D., and Heidi Klepin, M.D.
Manuscript Status Update
NCCTG and ACOSOG Collaborations
Annam Jato, M.D., and Jeanean Hubbard, M.D., NCCTG
Lisa Newman, M.D., M.P.H., and Waddah Al-Refaie, M.D., ACOSOG
PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS COMMITTEE
Saturday June 25, 8 am - 10 am, Back Bay A, 2nd Floor
Chair
Mark Matin, M.D.
Vice Chair
Lionel Lewis, M.B., B.Chir., M.D.
Howard McLeod, Pharm.D.
Antonius Miller, M.D.
Chemotherapy-Induced Peripheral Neuropathy
Ellen M. Locave, Smith, Ph.D, A.PRN.,B.C., A.O.C.N.
Protocol Review
Pharmacogenomic Studies
40101 Cyclophosphamide and doxorubicin (CA x 4 cycles) versus paclitaxel ( 4 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: a phase III randomized study [Genome-wide analysis of toxicity with adjuvant treatment of breast cancer]
Deanna Kieoz, Ph.D.
90401 A randomized double-blind placebo controlled phase III trial comparing doxetaxel and prednisone with and without bevacizumab (IND #7921, NSC #704865) in men with hormone refractory prostate cancer [Genome-wide analysis of outcomes after doxetaxel and bevacizumab treatment of prostate cancer]
Howard McLeod, Pharm.D.
Disease Procession Modeling
60806 Retrospective evaluation of change in tumor size as a marker of drug activity in CALGB trials of NSCLC
Mari Sharma, M.D., and Michael Hostland, M.D., Ph.D.
Chemotherapy-induced peripheral neuropathy
Mari Sharma, M.D., and Kauras Dewar, Ph.D.
Population Pharmacokinetics
Notable
Maria Boer, M.D., and Lionel Lewis, M.B., B.Chir., M.D.
Abiraterone
Charles Ryan, M.D., and Lionel Lewis, M.B., B.Chir., M.D.
Transplant Committee
Friday June 24, 2 pm – 5 pm, Back Bay A, 2nd Floor
Chair
Steven Devine, M.D.
Vice Chair
Thomas Shea, M.D.
Pre-emptive T-RAPA Cell DLI After Low-intensity Allogeneic HCT
Dan Fowler, M.D.
Head, Cytoxal Biology Section
Experimental Transplantation and Immunology Branch
National Cancer Institute
Overview of CALGB Transplant Committee Activity
Steven Devine, M.D.
Protocol Review
Active
100103 A phase II study of allogeneic transplant for older patients with AML in first morphologic complete remission using a non- myelotoxicative preparative regimen
Steven Devine, M.D.
100601 Reduced-intensity allogeneic hematopoietic cell transplantation as second transplantation for patients with disease relapse or myelodysplasia after prior autologous transplantation
Asad Bashey, M.D.
100701 Phase II study of reduced-intensity allogeneic stem cell transplant for high-risk chronic lymphocytic leukemia (CLL)
Howard McLeod, Pharm.D.
100801 Phase II study of the addition azacitidine (NSC #102816) to reduced-intensity conditioning allogeneic transplant for myelodysplasia (MDS) and older patients with AML
Aaron Koup, M.D.
107101 A phase II study of dasatinib (Sprycel) (IND #73969, NSC #732517) as primary therapy followed by transplantation for adults >/= 50 years with newly diagnosed Philadelphia acute lymphoblastic leukemia by CALGB, EOCOG, SWOG and NCI CTG
Meir Weiner, M.D.
In Development
100901 A phase I study of the allogeneic stem cell transplantation using reduced intensity conditioning regimen for relapsed high-risk peripheral T-cell lymphoma
Steven Devine, M.D.
101001 A randomized phase II study of intensive mobilization therapy followed by autologous stem cell transplantation with or without lenalidomide maintenance in high-risk patients with relapsed diffused large B-cell lymphoma
Babie Andreao, M.D.
Closed
100101 A phase II trial of intravenous pentostatin for the treatment of patients with refractory chronic graft-versus-host disease
Steven Devine, M.D.
100104 A phase III randomized, double-blind study of maintenance therapy with CC-5031 (NSC #703813, IND #701-16) or placebo following autologous stem cell transplantation for multiple myeloma
Babie Andreao, M.D.
10503 Phase II study of maintenance therapy with decitabine (NSC #127716, IND 50731) following standard induction and cytogenetic risk-adapted intensification in previously untreated patients with AML <60 years
William Slum, M.D.
50403 A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemoimmunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma
Lawrence Kaplan, M.D.
SCIENTIFIC RESOURCE COMMITTEES
CLINICAL RESEARCH ASSOCIATES COMMITTEE
Thursday,June 23, 1 pm – 5 pm, Republic B, 2nd Floor
Chair
Kandie Darnpey, M.S., RN, ONC, C.CRP.
Vice Chair
Barbara Barrett, M.S., C.CRP.
CALGB Central Office Update
Tani Apea, M.M.
Statistical Center Update: Query Tracking System
Elizabeth Bennet
CALGB Specimen Tracking System
Lind McCart
PCD Coordinator, CALGB Pathology Coordinating Office
The Ohio State University
Office of Human Research Protection Compliance
Overight Investigations (COI)
Lisa Rooney, J.D.
Compliance Oversight Coordinator
Office for Human Research Protection (OHRP)
Research Oversight: Community Clinical Oncology Program (CCOP) Site Perspectives
Marg Good, R.N., M.P.H., O.C.N.
National Cancer Institute
NCI Central Institutional Review Board
Jacquelyn L. Goldberg, J.D.
Marg Good, R.N., M.P.H., O.C.N.
National Cancer Institute CRB Initiative
PCO Coordinator, CALGB Pathology Coordinating Officer
The Ohio State University
Office of Human Research Protection Compliance
Overight Investigations (COI)
Lisa Rooney, J.D.
Compliance Oversight Coordinator
Office for Human Research Protection (OHRP)
Research Oversight: Community Clinical Oncology Program (CCOP) Site Perspectives
Marg Good, R.N., M.P.H., O.C.N.
National Cancer Institute
NCI Central Institutional Review Board
Jacquelyn L. Goldberg, J.D.
Cancer and Leukemia Group B Summer Group Meeting 2011

**Imaging Committee**
Friday, June 24, 10 am - 12:30 pm, Independence East, 2nd Floor
Chair: Lawrence Schwartz, M.D.
Vice Chairs: Nathan C. Hall, M.D., Ph.D.

**Randomized Phase III Study in Carcinoid**
**Trial Accrual and Data Collection Update**
Jan Zhang, Ph.D.
Update / CALGB 80003: Phase II Trial of PET Scan-directed Combined Modality Therapy in Esophageal Cancer
Nathan C. Hall, M.D., Ph.D.

**Protocol Review**
Active
40502 A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB-paclitaxel or sunitiibine combined with chemotherapy as first-line therapy for locally recurrent or metastatic breast cancer
Deanna L. Kroetz, Ph.D.

40503 Endocrine therapy with or without anti-VEGF therapy: A randomized phase III trial of endocrine therapy alone or endocrine therapy plus bevacizumab (NSC 704665: IND 7921) for women with hormone receptor-positive advanced breast cancer
Federico Innocenti, M.D.

50303 Phase III randomized study of R-CHOP vs. dose-adjusted EPOCH-R with molecular profiling in untreated de novo diffuse large B-cell lymphomas
Helga Schoder, M.D.

80302 A phase II trial of preoperative inotrectinib, capcitabine and radiation in esophageal cancer
Nathan Hall, M.D., Ph.D.

140503 A phase III trial of lobectomy versus sublobar resection for small (<1/2 cm) peripheral non-small cell lung cancer
Ernest Scalzetti, M.D.

80802 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Lale Kostakoglu, M.D.

50604 Phase II trial of ofatumumab-bendamustine vs. ofatumumab, bortezomib and bendamustine in patients with untreated follicular lymphoma
Lindsey H. Waltz, M.D.

50904 A randomized phase II trial of ofatumumab-bendamustine vs. ofatumumab, bortezomib and bendamustine in patients with untreated follicular lymphoma
Lawrence Schwartz, M.D.

80303 A randomized phase III trial of gemcitabine plus bevacizumab (NSC #704665 IND #7921) versus gemcitabine plus placebo in patients with advanced pancreatic cancer
Ernest Scalzetti, M.D.

50201 A phase II study to evaluate the safety and efficacy of Zevalin (IND #186 IND #11023) therapeutic regimen in patients with transformed CD30+ B-cell non-Hodgkin lymphoma
Lawrence Schwartz, M.D.

50203 Phase II trial of docetaxel, vinblastine and gemcitabine (AVG) chemotherapy for non-bulky stage I and II Hodgkin lymphoma
Mohd Jawad, M.D.

50404 A phase II study of rituximab + oblimersen sodium (Genasense, G3139, NSC #683428, IND #58842) in patients with previously untreated follicular non-Hodgkin lymphoma
Mohd Jawad, M.D.

50602 A phase II trial of galiiximab (anti-CD80) for patients with relapsed/refractory Hodgkin lymphoma
Heiko Schoder, M.D.

50701 A phase II trial of extended induction etoposide+cisplatin (anti-CD22 monoclonal antibody) (CALGB IND #101241) plus rituximab in previously untreated follicular non-Hodgkin lymphoma (NHL)
Loic Kesteloot, M.D.

**Radiation Oncology Committee**
Saturday, June 25, 2 pm - 4 pm, Republic A, 2nd Floor
Chair: A. William Blackstock, M.D.
Vice Chairs: A. William Blackstock, M.D.; Mark Hurwitz, M.D.

**History of the CALGB Radiation Oncology Committee**
Jeffrey Bogart, M.D.

**Protocol Review**
Active
30604 A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small cell lung cancer
Michael Samuels, M.D.

30609 A randomized phase III comparison of standard radiotherapy (63 Gy) versus high-dose conformal radiotherapy (74 Gy) with concurrent and consolidation carboplatin/paclitaxel in patients with stage IIIA/IIIB non-small cell lung cancer
A. William Blackstock, M.D., and Jeffrey Bogart, M.D.

30610 Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide
Jeffrey Bogart, M.D.

80302 Phase II trial of preoperative inotrectinib, capcitabine and radiation in esophageal cancer
Harvey Macon, M.D., Ph.D.

50604 Phase II trial of response-adapted chemotherapy based on positron emission tomography for non-bulky stage I and II Hodgkin lymphoma
John Greucis, M.D.

50801 Phase II trial of response-adapted therapy based on positron emission tomography (PET) for bulky stage I and stage II classical Hodgkin lymphoma (HL)
Christopher Kelsey, M.D.

In Development
81001 Neoadjuvant FOLFOX without planned pelvic radiation therapy for good risk locally advanced rectal adenocarcinoma
A. William Blackstock, M.D.

**Surgery Committee**
Saturday, June 25, 8 am - 10 am, Republic A, 2nd Floor
Chair: Leslie Kohan, M.D.
Vice Chair: Judy Smith, M.D.

**Opening Remarks**
Leslie Kohan, M.D.

**Introduction of Surgical Residents**
Leslie Kohan, M.D.

**CALGB Statistical Center**
Linda Bressler, Pharm.D.

**CRA Committee**
Chair: Kandie Dempsey, M.S., R.N., O.C.N., C.C.R.P.
Vice Chair: Barbara Barrett, M.S., C.C.R.P.

**U.S. Food and Drug Administration Final Rule & Revised CTEP Guidelines for Expedited Reporting of Adverse Events**
Linda Brezler, Pharm.D.

**CALGB 80802 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)**
Ghanian Abo-Afife, M.D.

**Neuroendocrine and Adeno-Pancreatic Tumors**
How They Relate to CALGB 80701
Emily Bergsland, M.D.

**Workshops / Lectures**

**Audit Preparation Workshop**
Thursday, June 23, 5:30 pm - 8 pm, Back Bay A & B, 2nd Floor
Chair: David Hunt, M.D.
Vice Chair: Susan Tuttle, R.N.

**Welcome / Audit Resources**
Barbara Barrett, M.S., C.C.R.P.

**Introduction to Data Auditing**
David Hunt, M.D.

**Institutional Review Board Audit Preparations**
Susan Tuttle, R.N.

**Timeline for Preparation and Toggling of Charts**
Debra Hezans, R.N.

**Pharmacy**
Susan Tuttle, R.N.

**Responding to the Audit Findings and Correction**
Barbara Barrett, M.S., C.C.R.P.

**WORKSHOPS / LECTURES**

**CRA Continuing Education**
Friday, June 24, 8 am - 12 pm, Back Bay A & B, 2nd Floor
Chair: Kandie Dempsey, M.S., R.N., O.C.N., C.C.R.P.
Vice Chair: Barbara Barrett, M.S., C.C.R.P.

**U.S. Food and Drug Administration Final Rule & Revised CTEP Guidelines for Expedited Reporting of Adverse Events**
Linda Brezler, Pharm.D.

**CALGB 80802 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)**
Ghanian Abo-Afife, M.D.

**Neuroendocrine and Adeno-Pancreatic Tumors**
How They Relate to CALGB 80701
Emily Bergsland, M.D.

**CRA Workshop for Cancer Control Studies**
Friday, June 24, 3 pm - 5 pm, Republic A, 2nd Floor
Chair: Electa Paskett, Ph.D.
Vice Chair: Ann Partridge, M.D., M.P.H.

**Protocols**
Active
70501 Collection of patient-reported symptoms and performance status via the internet [comparison to 30607, 30704, 40502, 40503, 40601, 40603, 70604, 80405, 90401]
Lauren Rogak, M.A.

70305 A randomized study to prevent lymphedema in women treated for breast cancer
Electa Paskett, Ph.D.
SYMPOSIA
Correlative Science Symposium
Friday-June 24, 2 pm - 4 pm, Independence West, 2nd Floor
Biospecimen and Correlative Science Advisory Committee Chair Philip Febo, M.D.
Director, Biospecimen and Correlative Science Operations Paula Friedman, Ph.D.

Inherited Genetic Variation in FGFD4 and PPARgamma-induced Peripheral Neuropathy: Results from a Genome-wide Association Study in CALGB 40101
Michael Baldwin, Ph.D., DSc.
University of California San Francisco

Whole Genome Sequencing and Analysis in the Clinical Trial Setting
Elaine Mandi, Ph.D.
Washington University

CALGB 150007 (I-SPY) – Genomic Predictor of Response and Survival Following Neoadjuvant Taxane-antichemotherapy Chemotherapy for Breast Cancer
Christos Hatzis, Ph.D.
Nuvion Bioinovations, Inc. (in collaboration with the MDACC Pharmacogenomics Program)

Validation of a 12-gene Colon Cancer Recurrence Score (RS) in Stage II Colon Cancer (CC) Patients (pts) from CALGB 9581
Marteide Paskett, Ph.D.

Prognostic and Predictive Blood-based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB 80303
Andrew Nixon, Ph.D.

Statistical Symposium
Saturday-June 25, 8 am - 10 am, Constitution A, 2nd Floor
CALGB Group Statistician Daniel J. Sargent, Ph.D.

What is an Adaptive Design and When Should It Be Used?
Daniel J. Sargent, Ph.D.

What are the Disadvantages to Using an Adaptive Design
Daniel J. Sargent, Ph.D.

Opportunities and Challenges in the Design and Implementation of Enrichment Trials
Susan Hoda, Ph.D.

A Case Study: Signature-Driven Biologic Therapy in Luminal B Metastatic Breast Cancer
Small Group Discussion of Case Study
Results of Small Group Discussion
Chosen Trial Design: Signature-Driven Biologic Therapy in Luminal B Metastatic Breast Cancer
William T. Burty, Ph.D.

20 YEARS
Pearl M. Alberts
Oncology Nursing/Data Management
08/30/1991 Mission Hospitals, Inc.

Marlene Johns
Oncology Nursing/Data Management
03/22/1991 Christiana Healthcare Services, Inc.

Rosealie O’Connor-Reing
Oncology Nursing/Data Management
04/08/1991 Mount Sinai School of Medicine

Lisa A. Zorlich
Oncology Nursing/Data Management
04/08/1991 Northeast Hospital Corporation - Addinkin Gilbert

15 YEARS
Pamela Bakalanski
Data Management
05/18/1996 Rhode Island Hospital

Kathryn S. Candler
Data Management
09/04/1996 Virginia Commonwealth University

Melinda DeLuca
Data Management
03/19/1996 Memorial Sloan-Kettering Cancer Center

Michael A. Hohenstein
Oncology Medical Data Management
01/10/1996 University of Nebraska Medical Center

M. Grace Rodriguez
Oncology Nursing
04/17/1996 University of Nebraska Medical Center

Consuelo Sazassy
Oncology Nursing/Data Management
06/17/1996 University of Chicago

Beverly A. Smith
Oncology Nursing/Data Management
06/17/1996 St. Mary’s Medical Center

10 YEARS
Diona M. Adams
Data Management
11/21/2001 Duke University Medical Center

Diona Angel
Data Management
03/12/2001 Wake Forest University School of Medicine

Lynda L. Artman
Data Management
09/20/2001 University of Bronx at Chicago

Carolyn S. Brown-Francis
Data Management
09/26/2001 Duke University Medical Center

Lori C. Cax
Data Management
09/10/2001 Danville Regional Medical Center

Beth L. Edwards
Oncology Nursing
06/12/2001 Alegent Health Bergan Mercy Medical Center

Lyndon Evans
Oncology Nursing/Data Management
10/17/2001 Greenville

Sarah S. Gorak
Data Management
02/23/2001 Illinois Oncology Research Association

Sharon S. Grandham
Oncology Nursing/Data Management
02/02/2001 Wayne Memorial Hospital

Clarice Halverson
Data Management
07/16/2001 University of Iowa

Julie A. Haney
Oncology Nursing/Data Management
05/01/2001 Roswell Park Cancer Institute

Linda phantom, Ph.D.
Oncology Nursing/Data Management
05/23/2001 Roswell Park Cancer Institute

Mary A. Huesting
Oncology Nursing/Data Management
06/08/2001 Canin Regional Cancer Center

Connie G. Honeycutt
Oncology Nursing/Data Management
06/08/2001 Virginia Commonwealth University

Cathy B. Jenkins
Oncology Nursing/Data Management
04/11/2001 Margaret R. Pardee Memorial Hospital

Jaya Kamath
Data Management
05/02/2001 Nepal Cancer Research Foundation

Jodi R. Lee
Oncology Nursing/Data Management
05/02/2001 The Ohio State University Medical Center

Deborah-L. Lewis
Oncology Nursing/Data Management
06/08/2001 Carolina Medical Center

Cheryl Lyons
Oncology Nursing/Data Management
08/07/2001 Northern Indiana Cancer Research Consortium

Julie A. Mulsant
Eastern Maine Medical Center

Patricia Meyn
Oncology Nursing/Data Management
02/22/2001 Long Island Jewish Medical Center

Rand P. Mohler
Data Management
03/12/2001 Wake Forest University School of Medicine

Susan L. Ottman
Oncology Nursing/Data Management
01/23/2001 The Ohio State University Medical Center

Beth M. Prue
Oncology Nursing/Data Management
01/23/2001 Wake Forest University School of Medicine

Shirley A. Rodriguez
Oncology Nursing/Data Management
03/27/2001 University of Chicago

Dallastine Rush
Data Management
02/28/2001 University of Chicago

Linda H. Schmieder
Oncology Nursing/Data Management
03/16/2001 Roswell Park Cancer Institute

Carmel A. Serowski
Oncology Nursing/Data Management
02/01/2001 Hamilton Hospital

Rocio Silva
Data Management
02/22/2001 Long Island Jewish Medical Center

Christine M. Smith
Data Management
09/16/2001 Richard Memorial Hospital

Mary S. Standle
Oncology Nursing/Data Management
05/23/2001 Gaston Memorial Hospital

Beth A. Stone
Oncology Nursing/Data Management
12/19/2001 Novant Health

Paula Walsh
Data Management
05/01/2001 University of California at San Francisco - Mount Zion

Dolores A. Webster
Oncology Nursing/Data Management
05/22/2001 North Shore University Hospital

Thomas E. Webster
Oncology Nursing
03/28/2001 Illinois Oncology Research Association

Patricia A. Welch
Oncology Nursing/Data Management
07/11/2001 Illinois Oncology Research Association

Rebecca L. Widoowski
Oncology Nursing/Data Management
08/31/2001 Women and Infant's Hospital of Rhode Island

Patricia A. Young
Oncology Nursing/Data Management
05/31/2001 FirstHealth of the Carolinas-Moore Regional Hospital

5 YEARS
Diane L. Arrington
Data Management
07/31/2006 Illinois Oroncology Research Assessment

Gina A. Aronson
Data Management
08/15/2006 Palo Alto Medical Foundation, Carino Division

Anna L. Bartt
Data Management
05/20/2006 Memorial Sloan-Kettering Cancer Center

Cancer and Leukemia Group B Summer Group Meeting 2011
5-Years continued

Mare C. Bates  Oncology Nursing/Data Management 03/14/2006 Premier Oncology Hematology Associates
Lin Bauer  Oncology Nursing/Data Management 09/25/2006 University of Nebraska Medical Center
Sharon W. Bell  Oncology Nursing/Data Management 05/08/2006 Marcon L. Sigepir Cancer Center
Judy L. Bentley  Oncology Nursing 02/15/2006 Northeast Medical Center
Sheri Bronahan  Oncology Nursing/Data Management 03/06/2006 Northeast Medical Center
Patricia L. Buruto  Data Management 08/29/2006 Roswell Park Cancer Institute
Caroline M. Bumb  Data Management 04/25/2006 Washington University School of Medicine
Terry D. Burke  Oncology Nursing 03/13/2006 University of Nebraska Medical Center
Vilma E. Calderon  Oncology Nursing/Data Management 01/13/2000 Mount Sinai Medical Center
Mary L. Cesar  Oncology Nursing/Data Management 06/19/2000 Memorial Sloan-Kettering Cancer Center
Kathryn Chamberlain  Oncology Nursing/Data Management 08/10/2000 Sidney Memorial Hospital
Carla E. Christiansen  Oncology Nursing/Data Management 12/27/2000 Presbyterian Health Services Corporation
Susan Coolkey  Oncology Nursing/Data Management 01/06/2000 Cooper Hospital/University Medical Center
Mary Ellen Coplan  Oncology Nursing 05/09/2000 Memorial Sloan-Kettering Cancer Center
Melissa A. Cook  Oncology Nursing/Data Management 07/11/2000 Nio Abo Medical Foundation, Centro Division
Janet E. Cooper  Oncology Nursing/Data Management 07/13/2000 University of Nebraska Medical Center
Terry A. Del Rio  Oncology Nursing 07/05/2000 Mount Sinai Medical Center
Bridget Dennis  Oncology Nursing 12/14/2000 Allegheny-Singer Research Institute
Virginia L. Doran  Data Management 08/27/2000 Roswell Park Cancer Institute
Gadwyn L. Oviano  Oncology Nursing/Data Management 02/17/2000 Christiana Healthcare Services, Inc.
Joanne Dymek  Oncology Nursing 03/14/2000 Weil Medical College of Cornell University
Volker K. Feiler  Oncology Nursing/Data Management 12/19/2000 Everet Hospital
Nicholas M. Fitcher  Oncology Nursing/Data Management 01/02/2000 Washington University School of Medicine
Nancy M. Folkett  Oncology Nursing 07/07/2000 Memorial Hospital of Rhode Island
Edith C. Fontana  Oncology Nursing 12/05/2000 Mountainview Medical
Michelle L. Garrage  Oncology Nursing 05/12/2000 Women and Infants Hospital of Rhode Island
Galilea L. Geho  Oncology Nursing 07/05/2000 Virginia Oncology Associates
Sharon P. Ginski  Oncology Nursing/Data Management 02/15/2000 University of Illinois at Chicago
Kimberly B. Godfrey  Oncology Nursing/Data Management 09/21/2002 Greenville
Virginia A. Grace  Oncology Nursing 11/11/2002 Dana-Farber Cancer Institute
Nancy Haefling  Oncology Nursing 02/24/2002 Northshore University HealthSystem
Cherie L. Hermann  Oncology Nursing 07/14/2000 Dartmouth Medical School - NCCO
Lantosy S. Hobbs  Oncology Nursing 06/12/2000 Duke University Medical Center
Richard V. Jakacki  Oncology Nursing 05/11/2000 The Ohio State University Medical Center
Mary J. Jarrah  Oncology Nursing/Data Management 08/02/2000 Minneapolis Veterans Administration Medical Center
Edwina Joyce  Oncology Nursing 06/19/2000 Memorial Sloan-Kettering Cancer Center
Katie Karolinski  Oncology Nursing 01/22/2000 University of Chicago
Linda K. Krouse  Oncology Nursing 03/22/2000 Dartmouth Medical School - NCCO
Jennifer Knotts  Oncology Nursing 07/14/2000 Virginia Oncology Associates
Mary Ann J. Koest  Oncology Nursing/Data Management 02/15/2000 University of Illinois at Chicago
Casey L. Kruse  Oncology Nursing 05/09/2000 Northern Indiana Cancer Research Consortium
Rebecca K. Kunzel  Oncology Nursing 09/12/2000 Illinois Oncology Research Association
Ellen LaGrata  Oncology Nursing 11/10/2000 Dana-Farber Cancer Institute
Sandra Langboth  Data Management 02/26/2000 St. Luke's Hospital
Georgia Litas  Oncology Nursing 11/08/2000 Dana-Farber Cancer Institute
Benjamin Crespo  Data Management 11/06/2000 Carolinas Medical Center
Rosemary Luker  Oncology Nursing/Data Management 01/06/2000 Northern Indiana Cancer Research Consortium
Daniel A. MacPherson  Oncology Nursing/Data Management 03/14/2000 Moses University of California San Diego Cancer Center
Angela Mahler  Oncology Nursing 08/23/2000 Virginia Oncology Associates
Janet Mari  Oncology Nursing/Data Management 07/28/2000 Women and Infants Hospital of Rhode Island
Janet B. Martin  Oncology Nursing/Data Management 05/15/2000 Joplin Medical Center
Georgia M. Malamore  Data Management 02/10/2000 Florida Hospital Cancer Institute
Karla K. Marris  Oncology Nursing 08/10/2000 Duke University Medical Center
Kathleen M. Muro  Oncology Nursing/Data Management 05/22/2000 Memorial Sloan-Kettering Cancer Center
Laurne A. Muxal  Oncology Nursing 04/13/2000 Roswell Park Cancer Institute

5-Years continued

Lisa N. Neel  Oncology Nursing/Data Management 07/24/2006 Virginia Oncology Associates
Heather R. Nutsch  Oncology Nursing/Data Management 02/24/2006 University of Nebraska Medical Center
Kristin B. Palm  Oncology Nursing/Data Management 05/16/2006 Grand Rapids Clinical Oncology Program
Dakota Pankiewicz  Oncology Nursing 06/29/2006 Advocate Illinois Masonic Medical Center
Christia H. Patterson  Oncology Nursing/Data Management 09/27/2006 Irland Memorial Hospital
Michelle D. Perkins  Oncology Nursing/Data Management 09/22/2006 Peninsula Regional Medical Center
Diane M. Perry  Oncology Nursing/Data Management 06/26/2006 Greenwich Hospital
Irene Piazza  Oncology Nursing 06/26/2006 Greenwich Hospital
Susan A. Pukala  Data Management 05/20/2006 Memorial Sloan-Kettering Cancer Center
Michelle A. Rainer  Oncology Nursing/Data Management 03/13/2000 University of Chicago
Jasmin H. Randall  Oncology Nursing/Data Management 12/11/2000 Presbyterian Health Services Corporation
Catherine A. Rhinestine  Oncology Nursing 09/10/2000 Dana-Farber Cancer Institute
Kim Roche  Oncology Nursing 08/09/2006 Sidney Memorial Hospital
Amy Rodriguez  Oncology Nursing/Data Management 08/31/2006 Mount Sinai School of Medicine
Bridget Sagreece  Oncology Nursing 02/14/2000 Saint Barnabas Medical Center
Karen Satter  Oncology Nursing 08/13/2006 Memorial Health University Medical Center
Sandra L. Schaevel  Oncology Nursing/Data Management 01/20/2000 Alegent Health Bergen Mercy Medical Center
Andrew Schumacher  Data Management 06/26/2000 Rhode Island Hospital
Camille A. Servodio  Oncology Nursing 11/07/2000 Hartford Hospital
Shawnda G. Simon  Data Management 11/08/2000 Carolinas Medical Center
Tara Sidmore  Data Management 01/20/2000 Carolinas Medical Center
Lena S. Shyrock  Data Management 06/16/2000 University of Nebraska Medical Center
Gay C. Smith  Oncology Nursing 09/20/2000 Virginia Commonwealth University
Shawn M. Stowin  Data Management 04/11/2000 Grand Rapids Clinical Oncology Program
Ingrid A. Svenson  Data Management 11/01/2000 Dartmouth Medical School - NCCO
Steven D. Thomas  Oncology Nursing 09/27/2000 State University of New York Upstate Medical Center
Kim Trautvois  Oncology Nursing 03/06/2000 Grand Rapids Clinical Oncology Program
Wendy L. Vandermeulen  Oncology Nursing 09/23/2000 Carolinas Medical Center
Eamala Vasudev  Oncology Nursing 05/10/2000 Massachusetts General Hospital
Sandra Walter  Oncology Nursing 10/19/2000 Grand Rapids Clinical Oncology Program
Deborah K. Wade  Oncology Nursing 08/29/2000 Virginia Oncology Associates
Kimberly E. Washington  Oncology Nursing/Data Management 11/01/2000 Dana-Farber Cancer Institute
Karen Weil  Oncology Nursing 09/21/2000 Weil Medical College of Cornell University
Christina M. Wells  Oncology Nursing 04/28/2000 Missouri Valley Cancer Consortium
Leslie L. Walsh  Oncology Nursing 10/17/2000 Virginia Oncology Associates
Amy M. Whitehead  Oncology Nursing 07/05/2000 Roswell Park Cancer Institute
Lynette Winnon  Oncology Nursing/Data Management 09/08/2000 St. Luke's Hospital
Lynn M. Wiewiorki  Oncology Nursing 07/03/2000 Roswell Park Cancer Institute
Andrea M. Wolf  Oncology Nursing/Data Management 09/29/2000 Roswell Park Cancer Institute
Jennifer A. Yamada  Data Management 05/20/2004 Memorial Sloan-Kettering Cancer Center
Jamie N. Yingst  Data Management 06/12/2000 Memorial Sloan-Kettering Cancer Center
HOTEL INFORMATION

Sheraton Boston Hotel
39 Dalton Street, Boston, Massachusetts 02199
800-325-3535 toll free
617-236-2000 local phone
617 236-1702 fax
http://www.starwoodhotels.com/sheraton

Location
The hotel is located in the heart of Boston’s Back Bay and is just steps from some of the city’s most popular attractions. Four miles from Logan Airport and blocks from the financial district, Charles River, trendy Newbury Street and Fenway Park.

Local Temperature
The average high temperature for June in Boston is 77 degrees; the average low is 59 degrees.

Internet Access
Internet is complimentary in the guest rooms for CALGB attendees. Rooms must have been booked in the CALGB room block. Wireless internet is available in the meeting space. To access wireless internet, choose “SherBosMtg” as your network. Then click into your internet browser. At the top right corner, click “Connect Now” on the Sheraton page. Select “Grand Ballroom” as your meeting room. The wireless code is ZZMW.

Ground Transportation
Taxi - The estimated taxi cost from Boston Logan International Airport to the hotel is $35 to $40.

Parking - Valet parking is available and includes in/out privileges. Garage parking at the Prudential Center cannot be billed back to the room and does not include in/out privileges. Parking is based on availability. Valet parking is $44 overnight (until 2 PM on day of check-out), and self parking (Prudential Center) is $39 for 24 hours.

Public Transportation - Option 1: From airport terminal, take a Massport shuttle bus to the airport subway station. Take an inbound Blue Line train to Government Center, then change to the Green Line. Take an “E-Health Street” Green Line train to Prudential station. Exit station into Prudential Center Mall. At center court, turn left into the Prudential Arcade and the hotel will be just past Au Bon Pain. The fare is $2. Option 2: From airport terminal, take any Silver Line bus to South Station, then change to the Red Line. Take an “Alewife” bound Red Line train to Park Street, then change at Park Street for the Green Line. Take an “E-Health Street” Green Line train to Prudential Station. Exit station into Prudential Center Mall. At center court, turn left into the Prudential Arcade and the hotel will be just past Au Bon Pain. The fare is $2.

FUTURE MEETINGS

2011 Fall Committee Meeting
September 15-17, 2011
The InterContinental Chicago O’Hare
Rosemont, IL

2011 Alliance Group Meeting
November 17-19, 2011
The InterContinental Chicago O’Hare
Rosemont, IL

*Closed meetings open to cadre members of committees or invited guests
Acknowledgements

The following have provided support to Cancer and Leukemia Group B research and educational programs in 2011.

Abraxis BioScience
Amgen, Inc.
Breast Cancer Research Foundation
Bristol-Myers Squibb Oncology
Celgene
Genentech BioOncology
Genomic Health, Inc.
GlaxoSmithKline
Millennium Pharmaceuticals
Novartis Oncology
OSI Pharmaceuticals
Pfizer, Inc.
Sanofi-Aventis

The Cancer and Leukemia Group B is a national cooperative group of 28 of the most prestigious medical centers with more than 200 affiliated institutions and 3,000 oncology specialists working together on large scale clinical trials.